Gastroenterologie up2date, Table of Contents Gastroenterologie up2date 2013; 09(03): 171-193DOI: 10.1055/s-0033-1344348 Leber/Galle/Pankreas © Georg Thieme Verlag KG Stuttgart · New York Adjuvante und palliative Therapie des Pankreaskarzinoms – Update Volker Kächele , Thomas Seufferlein Recommend Article Abstract Buy Article All articles of this category Full Text References Literatur 1 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249 2 Robert Koch Institut. Krebs in Deutschland 2007/2008. 8. . Aufl. Berlin: Robert Koch Institut; 2012: 48-52 3 Larsson SC, Permert J, Hakansson N et al. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer 2005; 93: 1310-1315 4 Hassan MM, Bondy ML, Wolff RA et al. Risk factors for pancreatic cancer: case control study. Am J Gastroenterol 2007; 102: 2696-2707 5 Wolpin BM, Chan AT, Hartge P et al. AB0 blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009; 101: 424-431 6 Amundadottir L, Kraft P, Stolzenberg-Solomon RZ et al. Genome-wide association study identifies variants in the AB0 locus associated with susceptibility to pancreatic cancer. Nat Genet 2009; 41: 986-990 7 Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009; 133: 365-374 8 Grützmann R, Niedergethmann M, Pilarsky C et al. Intraductal papillary micinous tumors of the pancreas: Biology, diagnosis and treatment. Oncologist 2010; 15: 1294-1309 9 Hartwig WMD, Hackert TMD, Hinz UM et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg 2009; 250: 81-87 10 Burdelski CM, Reeh M, Bogoevski D et al. Multivisceral resections in pancreatic cancer: Identification of risk factors. World J Surg 2011; 35: 2756-2763 11 van der Gaag NA, Rauws EAJ, van Eijck CHJ et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362: 129-137 12 Hennig R, Tempia-Caliera AA, Hartel M et al. Staging laparoscopy and its indications in pancreatic cancer patients. Dig Surg 2002; 19: 484-488 13 Pisters PW, Lee JE, Vauthey JN et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001; 88: 325-337 14 Berger AC, Garcia Jr M, Hoffman JP et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008; 26: 5918-5922 15 David M, Lepage C, Jouve JL et al. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer 2009; 101: 215-218 16 Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277 17 Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987; 60: 2284-2303 18 Carpelan-Holmstrom M, Nordling S, Pukkala E et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005; 54: 385-387 19 Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903 20 Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782 ; discussion 782-784 21 Neoptolemos JP, Dunn JA, Stocken DD et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-1585 22 Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210 23 Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299: 1019-1026 24 Ueno H, Kosuge T, Matsuyama Y et al. A randomized phase III trial comparing gemcitabine with surgery only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer 2009; 101: 908-915 25 Neoptolemos J, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081 26 Schmidt J, Abel U, Debus J et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012; 30: 4077-4083 27 Uesaka K, Fukutomi A, Boku N et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs. S-1 for resected pancreatic cancer patients. ASCO GI 2013; LBA 145 28 Esposito I, Kleeff J, Bergmann F et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008; 15: 1651-1660 29 Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185: 476-480 30 Picozzi V, Abrams R, Decker PA et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011; 22: 348-354 31 Friess H, Beger HG, Kunz J. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 1996; 16: 915-920 32 Wilkowski R, Thoma M, Schauer R et al. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004; 28: 1011-1018 33 Habermehl D, Kessel K, Welzel T et al. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiation Oncology 2012; 7: 28 34 Mukherjee S, Hurt CN, Brigdewater J et al. Gemcitabine-based or Capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013; 14: 317-326 35 Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19: 1592-1599 36 Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3496-3502 37 Le ScodanR, Mornex F, Girard N et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 2009; 20: 1387-1396 38 Huguet F, Andre T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331 39 Krishnan S, Rana V, Janjan NA et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55 40 Adler G, Seufferlein T, Bischoff SC et al. [S3-Guidelines „Exocrine pancreatic cancer“ 2007]. Z Gastroenterol 2007; 45: 487-523 41 Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600 42 Lutz MP, Koniger M, Muche R et al. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer. Z Gastroenterol 1999; 37: 993-997 43 Chabot JA, Tsai WY, Fine RL et al. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol 2010; 28: 2058-2063 44 Burris 3rd HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413 45 Sultana A, Smith CT, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615 46 Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438 47 Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275 48 Rocha LimaCM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783 49 Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516 50 Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645 51 Riess H, Helm A, Niedergethmann M et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. In: ASCO Annual Meeting Journal of Clinical Oncology; 2005 ASCO Annual Meeting Proceedings; Abstract 4009 2005 52 Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952 53 Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966 54 Cunningham D, Chau I, Stocken DB et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518 55 Poplin E, Feng Y, Berlin J et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 3778-3785 56 Kindler H, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3620 57 Philip P, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610 58 Colucci G, Labianca R, Di Costanzo F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 Study. J Clin Oncol 2010; 28: 1645-1651 59 Conroy C, Desseigne F, Ichou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 60 Ueno H, Ioka T, Ikeda M et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST Study. J Clin Oncol 2013; 31: 1640-1648 61 Rougier P, Riess H, Manges R et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer 30.06.2013; doi: [Epub ahead of print] 62 Von Hoff DD, Ervin T, Arena FP et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). ASCO GI 2013; LBA 148 63 Heinemann V, Vehling-Kaiser U, Waldschmidt D et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the “Arbeitsgemeinschaft Internistische Onkologie” (AIO-PK0104). Gut 2013; 62: 751-759 64 Abou-Alfa GK, Letourneau R, Harker G et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24: 4441-4447 65 Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-2217 66 Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-167 67 Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237 68 Kindler HL, Ioka T, Richel DL et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2012; 12: 256-262 69 Gonçalves A, Gilabert M, François E et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012; 23: 2799-2805 70 Tempero M, Plunkett W, Ruiz Van Haperen V et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-3408 71 Marechal R, Bachet JB, Mackey JR et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012; 143: 664-674 72 Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29: 4548-4554 73 Verslype C, Vervenne W, Bennouna J et al. Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. In: ASCO Annual Meeting Journal of Clinical Oncology; 2009 ASCO Annual Meeting Proceedings; Abstract 4532 2009 74 Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013; 31: 23-29 75 Trouilloud I, Dupont-Gossard C, Artru P et al. FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM. J Clin Oncol 2012; 30 (Suppl.) Abstract 4018 76 Pelzer U, Stieler J, Roll L et al. Second-line therapy in refractory pancreatic cancer. Results of a phase II study. Onkologie 2009; 32: 99-102 77 Pelzer U, Schwaner I, Stieler J et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676-1681 78 Boeck S, Heinemann V. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 2008; 26: 1178-1179 79 Boeck S, Weigang-Kohler K, Fuchs M et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 2007; 18: 745-751 80 Sudo K, Yamaguchi T, Nakamura K et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011; 67: 249-254 81 Yoo C, Hwang JY, Kim JE et al. A randomised phase II study of modified FOLFIRI. 3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101: 1658-1663 82 Kulke MH, Blaszkowsky LS, Ryan DP et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25: 4787-4792 83 Wolpin BM, Hezel AF, Abrams T et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009; 27: 193-198 84 Moertel CG, Frytak S, Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-1710 85 Loehrer P, Feng Y, Cardenes H et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29: 4105-4112
